Compare BridgeBio Pharma Inc (BBIO) vs Roblox Corp (RBLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Roblox Corp — how do they compare? BridgeBio Pharma Inc trades at $83.27 (market cap $16.46B), while Roblox Corp trades at $56.58 (market cap $39.00B). The key difference: Roblox Corp is far larger — about 2.4× BridgeBio Pharma Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Roblox Corp nearer its low. Which is the better fit depends on your goals.
| BBIO | RBLX | |
|---|---|---|
Market Cap | $16.46B | $39.00B |
Sector | Health | Media |
52-Week High | $90.17 | $141.56 |
52-Week Low | $44.81 | $41.30 |
Enterprise Value | $18.02B | $37.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
Roblox (RBLX) trades at $55.085, down 0.48% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $59.62. Revenue grew to $4.89 billion in 2025, though net losses persist at -$1.07 billion. The stock faces headwinds from multiple class-action lawsuits filed in July 2026 alleging securities fraud, but operational cash flow improved to $1.8 billion, supporting ongoing platform investments.
The outlook balances robust user growth and cash generation against profitability challenges and legal risks. Upside exists if monetization improves and legal issues resolve, but high P/B of 91.2 and negative margins warrant caution. Analysts remain predominantly bullish (51% buy ratings), viewing recent declines as a buying opportunity for long-term platform expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Roblox Corp
Roblox operates an online video game platform that lets young gamers create, develop, and monetize games (or experiences) for other players. The firm effectively offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning revenue in multiple places while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers then creating new games or franchises. Roblox is increasingly focused on creating a metaverse that moves beyond games toward experiences like concerts, education, and even business management.
Read more on RBLX →
